Clinical trial · Interventional
Pectoral Nerve Block and Serratus Posterior Superior Intercostal Plane Block in Breast Cancer Surgery
Analgesic Efficacy of Pectoral Nerve Block and Serratus Posterior Superior Intercostal Plane Block in Breast Cancer Surgery; Randomized Controlled Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This randomized clinical trial aims to evaluate and compare the analgesic efficacy of the Pectoral Nerve Block (PECS II) and the Serratus Posterior Superior Intercostal Plane (SPSIP) Block in patients undergoing breast cancer surgery. The primary outcome is total opioid consumption in the first 24 hours. Secondary outcomes include pain scores (VAS), block performance time, number of needle passes, postoperative recovery quality (QoR-15), time to first analgesic request, and complications (hematoma, pneumothorax, local anesthetic toxicity, vascular puncture, infection).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nerve Block | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PECS II Block | Procedure | — | UNRESOLVED |
| SPSIP Block | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- SPSIP Block
- description
- Patients in this group will receive an ultrasound-guided Serratus Posterior Superior Intercostal Plane (SPSIP) block with 30 mL of 0.25% bupivacaine hydrochloride injected into the fascial plane between the serratus posterior superior muscle and the third rib, 30 minutes before surgery.
- interventionNames
- Procedure: SPSIP Block
- type
- ACTIVE_COMPARATOR
- label
- PECS II Block
- description
- Patients in this group will receive an ultrasound-guided PECS II block with 30 mL of 0.25% bupivacaine hydrochloride (20 mL between the pectoralis minor and serratus anterior muscles, and 10 mL between the pectoralis major and minor muscles), 30 minutes before breast cancer surgery.
- interventionNames
- Procedure: PECS II Block
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Female patients aged 18-65 years * American Society of Anesthesiologists (ASA) physical status I-III * Body Mass Index (BMI) less than 35 kg/m² * Unilateral breast cancer surgery Exclusion Criteria: * Patient refusal to participate * BMI greater than or equal to 35 kg/m² * ASA physical status IV-V * Known allergy to any study medications * Pregnancy or breastfeeding * Presence of neuromuscular diseases * Chronic opioid use * Chronic pain syndromes * Significant organ failure (e.g., cardiac, hepatic, renal) * Contraindications to regional nerve blocks * Bilateral breast surgery
References
Publications (0)
Data not yet available